| NUGALVIQ Applied Therapeutics, Inc
2117762 30 Jun 2021 | on 29 Nov 2024 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for treatment of rare orphan diseases; Pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; Pharmaceutical preparations for inhibiting aldose reductase; Pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) and PMM2-congential disorder of glycosylation (PMM2-CDG) | | | NUGALVIQ & Design Applied Therapeutics, Inc.
2140735 18 Oct 2021 | on 29 Nov 2024 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for treatment of rare orphan diseases; pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; pharmaceutical preparations for inhibiting aldose reductase; pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) deficiency and PMM2-congenital disorder of glycosylation (PMM2-CDG) | | 
